-Bloomberg   In all likelihood, Nandan Nilekani's Aadhaar will lead the world. Exactly where it will lead, we'll find out People who grew up in Britain in the 1960s will remember a television programme that built a cult following: The Prisoner. It was about an oddly luxurious detention camp-a kind of Guantanamo Bay by Four Seasons, spa services and brainwashing included. Even if you wanted to, trying to escape was pointless. A...

-Frontline   The Supreme Court's ruling against Novartis' patent claim for the cancer drug Glivec paves the way for generic drug companies to keep crucial, life-saving drugs affordable to the common people. By V. VENKATESAN IN their 112-page judgment delivered on April 1, Justice Aftab Alam and Justice Ranjana Prakash Desai of the Supreme Court began with a simple proposition: in order to understand what the law really is, it is essential to...

-The Hindustan Times Amid raging controversy over regulation of electronic media in India, the Delhi High Court on Tuesday recommended to the government to establish a statutory body to regulate the broadcast media, saying state intervention was necessary. "Absence of state intervention on its own is no guarantee of a rich media environment. On the contrary: to promote a media environment characterized by pluralism and diversity, State intervention is necessary," a bench...

-The Hindu Well before the Supreme Court rejected Novartis' application for patent for Glivec (Gleevec in the U.S.), drawing attention to the dichotomy of generic and patented drugs, activists have been demanding access to expensive drugs used in the treatment of cancer, hepatitis C and serious HIV. Trastuzumab is one such, used in the treatment of HER2+ type of breast cancer, which affects about one in four patients with the disease. Rough...

-The Business Standard Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG's patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker. This is because the judgement...